Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.51 |
| ▸ | KIT | P10721 | 6/20 | 0.51 |
| ▸ | AXL | P30530 | 5/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780687 | 1.00 | FLT3 (0.51) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4041616 | 0.88 | FLT3 (0.57) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL12780733 | 0.88 | FLT3 (0.57) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL12780688 | 0.83 | FLT3 (0.53) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL12780690 | 0.83 | FLT3 (0.53) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4043036 | 0.83 | FLT3 (0.53) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4041958 | 0.81 | FLT3 (0.51) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4046914 | 0.79 | FLT3 (0.54) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4045933 | 0.78 | FLT3 (0.70) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL13963948 | 0.77 | FLT3 (0.69) | FLT3KITAXLIRAK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612054-B2 | Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| EP-1651592-B1 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | APP, BACE1, BCHE | FLT3 2306/4885KIT 1387/4885AXL 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.